论文部分内容阅读
目的探讨依达拉奉治疗脑出血的效果及安全性。方法将80例脑出血患者随机分为治疗组和对照组,治疗组在常规治疗的基础上给予依达拉奉治疗,14 d为一疗程。分别比较两组治疗前及治疗后14 d和28 d神经功能缺损程度(national institute of health stroke scale,NIHSS),Glassgow评分,治疗前、后查血、尿常规,血浆凝血酶原时间(pro-thrombin time,PT),活化部分凝血活酶时间(activated partial thromboplastin time,APTT)和血浆纤维蛋白原(FG)、肝功能、肾功能、心电图。结果与对照组比较,治疗组治疗后14 d和28 d的NIHSS评分均低于对照组(P<0.05);Glassgow评分差异有统计学意义(P<0.05);治疗后血常规、尿常规、PT、APTT、FG、肝功能、肾功能、心电图与治疗前比较差异均无统计学意义(P>0.05);两组不良事件比较差异也均无统计学意义(P>0.05)。结论依达拉奉治疗脑出血能显著提高基本治愈率;依达拉奉治疗脑出血有效、安全。
Objective To investigate the efficacy and safety of edaravone in treating cerebral hemorrhage. Methods Eighty patients with intracerebral hemorrhage were randomly divided into treatment group and control group. The treatment group was treated with edaravone on the basis of routine treatment, and 14 days was a course of treatment. The levels of neurological deficit (NIHSS), Glassgow score before and after treatment, before and after treatment were compared between the two groups before and after treatment, blood and urine routine tests, pro- thrombin time (PT), activated partial thromboplastin time (APTT) and plasma fibrinogen (FG), liver function, renal function and electrocardiogram. Results Compared with the control group, NIHSS scores of the treatment group on the 14th and 28th day after treatment were lower than those of the control group (P <0.05); Glassgow scores were significantly different (P <0.05); after treatment, blood routine, urine routine, PT, APTT, FG, liver function, renal function, electrocardiogram were not significantly different from those before treatment (P> 0.05). There was no significant difference between the two groups in the incidence of adverse events (P> 0.05). Conclusion Edaravone treatment of cerebral hemorrhage can significantly improve the basic cure rate; Edaravone treatment of cerebral hemorrhage effective and safe.